Study guide
15.3 Adverse Reactions, Patient Safety & Emergency Management
IJCAHPO Certified Ophthalmic Medical Technologist COMT
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The COMT Examination, Eligibility & Certification Requirements
1.1 The 190-Question Multiple-Choice Examination & the 22 Official Content Areas 1.2 The COT Skill Evaluation & the COMT Performance Test 1.3 Eligibility Pathways, Fees, Timelines & Recertification
2 Chapter 2: General Medical Knowledge I — Ocular Anatomy & Physiology
2.1 Orbit, Eyelids, Lacrimal System, Conjunctiva & Extraocular Muscles 2.2 Cornea, Sclera, Anterior Chamber, Angle, Aqueous Dynamics & Crystalline Lens 2.3 Uvea, Retina, Vitreous, Optic Nerve, Ocular Circulation & the Visual Pathway
3 Chapter 3: General Medical Knowledge II — Eye Disease, Systemic Manifestations, Terminology & Safety
3.1 Frequently Encountered Eye Conditions by Structure & Inflammation Versus Infection 3.2 Body Systems & the Ocular Manifestations of Systemic Disease 3.3 Medical Terminology, Approved Abbreviations, Hazardous Waste & Clinic Safety
4 Chapter 4: Ophthalmic History Taking & Clinical Documentation
4.1 The Five History Domains: Ocular, Medical, Medication, Social & Family 4.2 Charting Conventions, Scribing & the Electronic Medical Record
5 Chapter 5: Visual Assessment, Accommodative Testing & Low Vision
5.1 Measuring Acuity at Every Level & in Preliterate, Illiterate and Non-Verbal Patients 5.2 Stereoacuity, Near Point of Accommodation, Near Point of Convergence & the AC/A Ratio 5.3 Low Vision Assessment, Magnification Calculation & Device Instruction
6 Chapter 6: Tonometry, Keratometry & Pupil Measurement
6.1 Goldmann Applanation Tonometry: Technique, Sources of Error & the Imbert-Fick Principle 6.2 Hand-Held Applanators, Non-Contact Tonometry, Rebound Tonometry & Disinfection 6.3 Manual & Automated Keratometry: Technique, Readings and Interpretation 6.4 Pupil Measurement, Shape, Reactivity & Evaluating Anisocoria
7 Chapter 7: Lensometry, Spectacle Optics & Prescription Analysis
7.1 Manual Lensometry: Eyepiece Focus, Neutralising Sphere, Cylinder & Axis 7.2 Neutralising Reading Adds: Bifocal, Trifocal, Progressive & Determining the Near Add 7.3 Identifying & Measuring Prism: Ground-In, Decentration, Fresnel Press-On & Slab-Off 7.4 Transposition, Spherical Equivalent, Vertex Distance & Prescription Components 7.5 The Geneva Lens Clock, Lens Materials, Progressive Markings & Spectacle Adjustment
8 Chapter 8: Refraction, Retinoscopy & Refinement
8.1 Autorefraction, Refractive Error Types & Establishing an Objective Starting Point 8.2 Streak Retinoscopy: With Motion, Against Motion, Neutralisation & Working Distance 8.3 Subjective Refinement: Fogging, Jackson Cross Cylinder, Duochrome & Binocular Balance 8.4 Near Add Determination, Vertex Recording & Refraction in Difficult Situations
9 Chapter 9: Ocular Motility, Strabismus & Advanced Optics
9.1 Ocular Kinematics: Ductions, Versions, Vergences, Hering's & Sherrington's Laws 9.2 Quantitative Strabismus Measurements: Alternate Cover Test, Prism Cover Test & Lancaster Red-Green / Hess Screen 9.3 Cranial Nerve Palsies (CN III, IV, VI), Restrictive Myopathies & Forced Duction Testing 9.4 Clinical Optics, Prentice's Rule, Slab-Off Prisms & Wavefront Aberrations
10 Chapter 10: Sensory Fusion Testing, Nystagmus, Amblyopia & Vergence Therapy
10.1 Sensory Fusion Testing: Worth 4-Dot, Maddox Rod & Bagolini Lenses 10.2 Hirschberg, Krimsky, Brückner & Fusional Vergence Amplitudes 10.3 Nystagmus, Amblyopia Therapy & Convergence Training
11 Chapter 11: Advanced Visual Fields & Neuro-Ophthalmic Evaluation
11.1 Amsler Grid & Confrontation Visual Field Testing 11.2 Automated Static Perimetry: HFA Strategies (SITA Standard, SITA Fast), Reliability Indices & Statpac Analysis 11.3 Visual Field Defect Patterns: Glaucomatous Nerve Fiber Bundle Deficits vs. Retinal Pathology 11.4 Kinetic Perimetry (Goldmann Perimetry) & Neurological Visual Pathway Defect Localization 11.5 Pupillary Pathways, RAPD Quantitation with Neutral Density Filters & Pharmacologic Testing
12 Chapter 12: Supplemental Testing — Glare, PAM, Colour Vision, Tear Film & Slit Lamp Technique
12.1 Glare Testing, Potential Acuity Meter & Contrast Sensitivity 12.2 Colour Vision: Pseudoisochromatic Plates, Farnsworth-Munsell D-15 & the 100-Hue Test 12.3 Tear Film Assessment: Schirmer, Tear Break-Up Time, Vital Dyes & Corneal Sensitivity 12.4 Slit Lamp Technique, Slit Lamp Lenses, Direct Ophthalmoscopy & Pen Light Examination 12.5 Exophthalmometry, Head & Posture Assessment and Wavefront Diagnostics
13 Chapter 13: Full-Field Electroretinography & ISCEV Protocols
13.1 Retinal Neurophysiology & Electrophysiologic Origin of Waveforms 13.2 ISCEV Standard Full-Field ERG Protocol & Electrode Systems 13.3 Dark-Adapted (Scotopic) Testing: Rod-Driven Responses & Combined Maximal Response 13.4 Light-Adapted (Photopic) Testing: Cone Response, 30-Hz Flicker & Oscillatory Potentials
14 Chapter 14: Advanced Electrophysiologic Testing (mfERG, PERG, VEP, EOG)
14.1 Multifocal Electroretinogram (mfERG): Topographic Retinal Mapping 14.2 Pattern Electroretinogram (PERG): Ganglion Cell & Macular Function 14.3 Visual Evoked Potentials (VEP): Flash, Pattern & Visual Pathway Integrity 14.4 Electrooculogram (EOG), Arden Ratio & RPE Light Peak Dynamics
15 Chapter 15: Fluorescein Angiography Principles & Technique
15.1 Fluorescein Angiography Principles, Exciter/Barrier Filters & Injection Protocol 15.2 Normal Transit Phases & Retinal/Choroidal Circulation Hemodynamics 15.3 Adverse Reactions, Patient Safety & Emergency Management
16 Chapter 16: Angiographic Interpretation & Pathology
16.1 Hyperfluorescence Mechanisms: Leakage, Staining, Pooling, Window Defects & Autofluorescence 16.2 Hypofluorescence Mechanisms: Vascular Non-Perfusion & Blocking Defects 16.3 Indocyanine Green (ICG) Angiography: Principles, Indications & Choroidal Pathology
17 Chapter 17: Advanced Fundus Imaging & Optical Coherence Tomography
17.1 Fundus Autofluorescence (FAF) & Ultra-Widefield Fundus Imaging 17.2 Spectral-Domain and Swept-Source OCT: Retinal Layer Architecture & Quantitative Analysis 17.3 Enhanced Depth Imaging (EDI-OCT) & Anterior Segment OCT (AS-OCT) 17.4 Optical Coherence Tomography Angiography (OCTA): Chorioretinal Plexuses & Biomarkers
18 Chapter 18: Ophthalmic Photography & Videography
18.1 The Fundus Camera: Optics, Alignment & Correcting Artefacts 18.2 Standard Fundus Photography: ETDRS Fields, Stereo Pairs, Red-Free & Wide-Field Imaging 18.3 Slit Lamp & Anterior Segment Photography 18.4 External Photography, Nine-Gaze Motility Documentation & Image Management
19 Chapter 19: Ophthalmic Echography (A-Scan, B-Scan & UBM)
19.1 Physics of Ophthalmic Ultrasound, Acoustic Impedance & Probe Transducers 19.2 Standardized Diagnostic A-Scan: Acoustic Spikes, Tissue Reflectivity & Attenuation 19.3 Diagnostic B-Scan Echography: Topographic, Kinetic & Quantitative Vitreoretinal Evaluation 19.4 Ultrasound Biomicroscopy (UBM): Anterior Segment Anatomy, Angle Pathology & Ciliary Body Imaging
20 Chapter 20: Biometry, Topography & Corneal Analysis
20.1 Optical Biometry vs. Immersion/Contact Ultrasound Biometry 20.2 Intraocular Lens (IOL) Power Calculation Formulas & Post-Refractive Adjustments 20.3 Corneal Topography, Scheimpflug Tomography & Keratoconus Screening 20.4 Corneal Pachymetry, Endothelial Specular Microscopy & Anterior Chamber Depth
21 Chapter 21: Rigid Gas Permeable & Specialty Lens Fitting
21.1 Rigid Gas Permeable (RGP) Material Properties, Dk/t & Oxygen Permeability 21.2 RGP Base Curve Selection, Diagnostic Fitting & Fluorescein Pattern Evaluation 21.3 Scleral Contact Lens Design, Sagittal Depth Fitting & Clearance Evaluation 21.4 Keratoconus, Irregular Corneas & Hybrid Contact Lens Systems
22 Chapter 22: Toric, Multifocal, Therapeutic Lenses & Complications
22.1 Toric Soft Contact Lens Dynamics, Stabilization Techniques & LARS Rule 22.2 Presbyopic & Multifocal Contact Lens Systems: Simultaneous vs. Translating Designs 22.3 Therapeutic Bandage Contact Lenses, Amniotic Membranes & Orthokeratology 22.4 Contact Lens-Induced Pathology, Giant Papillary Conjunctivitis & Infectious Keratitis
23 Chapter 23: Ocular Pharmacology
23.1 Routes of Drug Delivery, Prescription Components & Instillation Technique 23.2 Mydriatics, Cycloplegics, Anaesthetics & Diagnostic Agents 23.3 Glaucoma Medications: Classes, Mechanisms & Side Effects 23.4 Anti-Infectives, Corticosteroids, NSAIDs, Allergy Agents, Lubricants, Supplements & Anti-VEGF
24 Chapter 24: Microbiology & Ocular Specimen Collection
24.1 Types of Microorganisms & Pathways of Disease Transmission 24.2 Assisting with Conjunctival & Corneal Specimen Collection
25 Chapter 25: Anterior Segment, Glaucoma & Refractive Surgery
25.1 Advanced Phacoemulsification, Surgical Steps, Fluidics & Complication Management 25.2 Premium Intraocular Lenses: Toric, Multifocal, EDOF & Lens Exchange 25.3 Glaucoma Surgical Procedures: Trabeculectomy, Aqueous Shunts & MIGS Devices 25.4 Laser In Situ Keratomileusis (LASIK), PRK, SMILE & Phakic IOLs
26 Chapter 26: Vitreoretinal, Corneal & Trauma Surgery
26.1 Pars Plana Vitrectomy (PPV), Scleral Buckling & Intraocular Tamponades (Gas/Silicone Oil) 26.2 Corneal Transplantation: Penetrating Keratoplasty (PKP) & Lamellar Keratoplasty (DSAEK, DMEK, DALK) 26.3 Ocular Trauma Repair: Open Globe Management, Hyphema, Vitreous Loss & Endophthalmitis Protocol
27 Chapter 27: Surgical Asepsis, Instrumentation & Laser Procedures
27.1 Operating Room Sterilization, Aseptic Field Maintenance & Universal Precautions 27.2 Microsurgical Instrumentation, Maintenance & Sharps Safety 27.3 Ophthalmic Laser Physics, Delivery Systems & Safety (Nd:YAG, Argon/FD-Nd:YAG, SLT)
28 Chapter 28: Ophthalmic Patient Services & Education
28.1 Communicating with Patients, Families and Colleagues, and Handling Dissatisfaction 28.2 Patient Education & Counselling on Conditions, Medications, Tests and Results 28.3 Ophthalmic Emergencies, First Aid, Vital Signs & CPR 28.4 Triage, Urgency-Based Scheduling, Patient Flow & Telephone Management 28.5 Dressings and Shields, Prosthetics, Legal Forms, Referrals & Reimbursement Support
29 Chapter 29: Clinic Operations — Equipment Maintenance, Ethics, Coding & Compliance
29.1 Equipment Maintenance, Calibration, Emergency Equipment & Inventory 29.2 Confidentiality, Informed Consent, Scope of Practice & Ethical Standards 29.3 Coding, Scribing Compliance, Quality Assurance & Regulatory Requirements
15.3 Adverse Reactions, Patient Safety & Emergency Management
Key Takeaways Explain This Topic AI
Adverse reactions occur in 5% to 10% of patients; mild reactions (transient nausea in 3–10%, vomiting in 1–2%) are self-limiting and resolve within 1–3 minutes without medication.
Fluorescein reactions are predominantly non-IgE-mediated anaphylactoid (pseudoallergic) responses; seafood or radiopaque iodine allergies do not cross-react with sodium fluorescein.
First-line management for severe anaphylaxis is immediate intramuscular epinephrine 1:1,000 (1 mg/mL) at 0.3–0.5 mg in the anterolateral mid-thigh, repeated every 5–15 minutes as needed.
Patients on systemic beta-blockers experiencing anaphylaxis may exhibit severe refractory bronchospasm and hypotension resistant to epinephrine, requiring intravenous glucagon (1–5 mg).
Fluorescein is excreted in human breast milk; nursing mothers must express and discard milk for 24 to 48 hours post-procedure; it crosses the placenta and is generally contraindicated in pregnancy.
Last updated: September 2026
Adverse Reactions, Patient Safety & Emergency Management
Core Clinical Mandate: Intravenous sodium fluorescein is a diagnostic pharmacological agent with an established safety profile, but it is not benign. The overall incidence of adverse events ranges between 5% and 10%. Certified Ophthalmic Medical Technologists (COMTs) must maintain immediate readiness to distinguish benign, self-limiting side effects from acute, life-threatening anaphylactoid collapse, and must be proficient in emergency crash-cart mobilization and drug administration protocols.
Epidemiology and Classification of Adverse Fluorescein Reactions
Adverse events associated with sodium fluorescein administration are systematically classified into three clinical severity tiers based on symptomatology and required therapeutic intervention:
1. Mild Reactions (Incidence ~5% to 10%)
Mild reactions are transient, self-limiting, and resolve spontaneously within several minutes without specific medical intervention or pharmacotherapy:
Nausea: The most frequent adverse reaction, occurring in approximately 3% to 10% of patients. It characteristically develops 30 to 60 seconds post-injection (corresponding to the arrival of the concentrated dye bolus at the brainstem area postrema / chemoreceptor trigger zone), lasts for 1 to 3 minutes , and subsides spontaneously.
Vomiting / Emesis: Occurs in 1% to 2% of patients, usually immediately following the initial wave of nausea. Emesis basins must always be within arm's reach of the patient during angiography.
Autonomic / Mild Allergic Manifestations: Lightheadedness, mild dizziness, flushing, feeling of warmth, metallic taste in the mouth, localized pruritus, and transient paroxysmal sneezing.
Expected Physiological Side Effects: Yellow-orange chromaturia (lasting 24–36 hours) and cutaneous/scleral jaundice (lasting 6–12 hours) are universal physiological consequences of dye clearance and do not constitute adverse drug reactions.
2. Moderate Reactions (Incidence ~1%)
Moderate reactions are not immediately life-threatening but cause substantial patient distress and require prompt, targeted pharmacologic intervention:
Urticaria (Hives): Widespread cutaneous wheals and erythema, often accompanied by intense pruritus.
Angioedema: Soft-tissue swelling involving the periorbital area, lips, or extremities, without acute airway or laryngeal compromise.
Bronchospasm / Wheezing: Mild-to-moderate reactive airway constriction with audible expiratory wheezes, but maintaining oxygen saturation >92%.
Vasovagal Syncope: Sudden parasympathetic outflow resulting in bradycardia and systemic hypotension, causing transient loss of consciousness.
Local Thrombophlebitis: Chemical vein irritation or superficial phlebitis at the venipuncture site.
3. Severe / Life-Threatening Reactions (Incidence ~1 in 1,900 to 1 in 2,000)
Severe reactions represent acute medical emergencies requiring immediate cardiopulmonary resuscitation, emergency team activation (Code Blue / 911), and aggressive intensive care management:
Anaphylactic Shock: Acute cardiovascular collapse characterized by profound distributive hypotension (systolic blood pressure <90 mmHg), marked tachycardia, and peripheral hypoperfusion.
Laryngeal Edema: Massive supraglottic swelling leading to acute upper airway obstruction, inspiratory stridor, and asphyxia.
Severe Bronchospasm: Critical lower airway obstruction, severe dyspnea, cyanosis, and arterial hypoxemia.
Cardiovascular Events: Acute myocardial infarction, severe ventricular arrhythmias, or circulatory arrest.
Neurological Manifestations: Generalized tonic-clonic seizures.
Mortality Rate: Estimated at approximately 1 in 220,000 angiographic procedures.
Pathophysiological Mechanisms: Pseudoallergy vs. Type I Hypersensitivity
Historically, fluorescein reactions were presumed to be classical IgE-mediated (Type I) allergic hypersensitivity events. Extensive immunological research has fundamentally refuted this concept: Pathophysiology of Fluorescein Reactions:
Predominantly NON-IgE ANAPHYLACTOID (Pseudoallergic) Reaction:
- Direct Complement Activation (C3a, C5a) + Direct Mast Cell Histamine De-granulation
- (Does NOT require prior sensitizing exposure; skin testing has ZERO predictive validity)
Non-IgE-Mediated (Anaphylactoid / Pseudoallergic) Activation: The vast majority of severe reactions result from direct complement activation (generating anaphylatoxins C3a and C5a) and direct, non-immunological degranulation of basophils and mast cells , causing massive systemic release of histamine, tryptase, leukotrienes, and prostaglandins without preformed IgE antibodies.
No Prior Exposure Required: Because the mechanism is non-IgE-mediated, patients can develop severe, life-threatening anaphylactoid reactions upon their first lifetime exposure to sodium fluorescein.
Inefficacy of Skin Prick / Intradermal Testing: Intradermal or skin prick testing has a near-zero positive predictive value for forecasting anaphylactoid reactions and is clinically contraindicated as a predictive screening tool. Furthermore, the intradermal test dose itself can trigger severe systemic reactions.
Dispelling the Iodine and Shellfish Cross-Reactivity Myth
A pervasive and hazardous clinical misconception in ophthalmology is that patients with known allergies to shellfish or radiopaque iodinated CT contrast media cannot receive sodium fluorescein:
Molecular Reality: Sodium fluorescein (C₂₀H₁₀Na₂O₅) is a synthetic hydrocarbon resorcinolphthalein dye. It contains zero iodine molecules .
No Cross-Reactivity: Shellfish allergy is mediated by IgE antibodies directed against muscle tropomyosin , a muscle protein found in crustaceans and mollusks. It has absolutely no relationship to iodine or fluorescein.
Clinical Ruling: A documented history of seafood or radiocontrast dye allergy is NOT a contraindication to sodium fluorescein angiography .
Critical Distinction: In contrast to sodium fluorescein, Indocyanine Green (ICG) contains approximately 5% sodium iodide by weight; therefore, ICG is strictly contraindicated in patients with true iodine hypersensitivity.
Loading diagram... Emergency Response Algorithm for Acute Fluorescein Reactions
Emergency Preparedness and Rapid Clinical Response Protocols
Every ophthalmic imaging facility performing fluorescein angiography must maintain a fully stocked, routinely inspected Emergency Crash Cart , portable suction, oxygen delivery systems, and an automated external defibrillator (AED) in the immediate imaging suite.
Step-by-Step Acute Emergency Management Algorithm
Halt the Injection Immediately: At the earliest sign of severe respiratory distress, stridor, hypotension, or angioedema, stop injecting fluorescein instantly.
Maintain Patent Intravenous Access: DO NOT REMOVE THE IV CATHETER OR BUTTERFLY NEEDLE. Tape it securely and immediately flush with 0.9% normal saline. Maintaining established venous access is life-critical; peripheral veins collapse rapidly during anaphylactic shock, making emergent recannulation nearly impossible.
Call for Immediate Resuscitative Assistance: Activate the internal cardiac arrest team (Code Blue) or dial emergency medical services (911).
Patient Positioning:
For Hypotension / Anaphylactic Shock / Syncope: Place the patient in the Trendelenburg position (supine with lower extremities elevated 30° to 45°) to augment venous return to the heart and preserve cerebral perfusion.
For Laryngeal Stridor / Respiratory Distress: Maintain the patient in an upright or semi-Fowler's position if conscious to optimize diaphragmatic excursion, provided blood pressure is stable.
Airway, Breathing, Circulation (ABCs): Maintain an open airway; initiate bag-valve-mask ventilation if respiratory effort is compromised. Administer high-flow supplemental oxygen via a non-rebreather reservoir mask at 10 to 15 L/min .
First-Line Pharmacotherapy: Intramuscular Epinephrine
Epinephrine (Adrenaline) is the definitive, mandatory first-line medication for severe anaphylaxis, laryngeal edema, and acute bronchospasm. Antihistamines and corticosteroids are secondary adjuncts and must never delay epinephrine administration.
Formulation: 1:1,000 dilution (1 mg/mL aqueous solution).
Adult Dosage: 0.3 mg to 0.5 mg (0.3 to 0.5 mL).
Route and Site: Administered Intramuscularly (IM) into the anterolateral aspect of the middle third of the thigh (vastus lateralis) . The vastus lateralis provides vastly superior vascular absorption and achieves therapeutic plasma concentrations significantly faster than subcutaneous injection or deltoid intramuscular administration.
Repeat Dosing: May be repeated every 5 to 15 minutes depending on clinical response, blood pressure, and airway patency.
Pediatric Dosage: 0.01 mg/kg body weight of 1:1,000 IM (maximum single dose 0.3 mg).
Dangers of Intravenous Epinephrine: Intravenous bolus injection of 1:1,000 epinephrine is strictly contraindicated due to the extreme risk of lethal ventricular tachyarrhythmias, malignant hypertension, and myocardial infarction. (IV epinephrine is reserved exclusively for cardiac arrest or profound shock managed by critical care physicians using a 1:10,000 dilution titrated under continuous cardiac monitoring).
Secondary Emergency Pharmacotherapy Protocols
Medication Target Symptoms / Indication Adult Dosage & Route Mechanism & Onset
Epinephrine 1:1,000 Anaphylaxis, laryngeal edema, severe bronchospasm, shock 0.3–0.5 mg IM anterolateral mid-thigh; repeat q5–15 min Alpha-1 (vasoconstriction), Beta-1 (inotropy/chronotropy), Beta-2 (bronchodilation); Onset: 3–5 min
Diphenhydramine (Benadryl) Urticaria, severe pruritus, allergic angioedema 25–50 mg IV (slow push over 2 min) or IM H1-receptor antagonist; blocks histamine-mediated capillary dilation and wheal formation; Onset: 10–15 min
Famotidine / Ranitidine Adjunct for refractory anaphylaxis Famotidine 20 mg IV or Ranitidine 50 mg IV H2-receptor antagonist; synergizes with H1-blockers to prevent vasodilation; Onset: 15–30 min
Albuterol (Salbutamol) Acute bronchospasm, wheezing, reactive airway distress 2.5 mg nebulized in 3.0 mL 0.9% normal saline with O2 Selective Beta-2 agonist; relaxes bronchial smooth muscle; Onset: 5 min
Methylprednisolone (Solu-Medrol) Prevention of biphasic / protracted anaphylaxis 125 mg IV (or Hydrocortisone 100–200 mg IV) Glucocorticoid; inhibits inflammatory cytokine synthesis; Delayed onset (4–6 hours)
Atropine Sulfate Severe vasovagal bradycardia (HR < 50 bpm) with hypotension 0.5–1.0 mg IV push ; repeat q3–5 min (max 3.0 mg) Anticholinergic / parasympatholytic; blocks vagal input to SA and AV nodes; Onset: 1–2 min
0.9% Normal Saline Distributive anaphylactic shock, profound hypotension 1,000–2,000 mL IV bolus rapidly under pressure Crystalloid volume expansion; restores effective circulating intravascular volume; Immediate
Glucagon Refractory anaphylaxis in patients on Beta-Blockers 1–5 mg IV over 5 min, then 1–5 mg/hr IV infusion Stimulates adenylate cyclase via G-protein bypass; restores inotropy & bronchodilation; Onset: 5–10 min
- Special Clinical Populations, Risk Factors, and Premedication
- Patients Receiving Systemic Beta-Adrenergic Antagonists (Beta-Blockers)
Patients taking systemic beta-adrenergic antagonists (e.g., propranolol, metoprolol, atenolol, carvedilol) or topical ophthalmic beta-blockers (e.g., timolol) who experience severe anaphylaxis present a grave clinical scenario:
Pathophysiological Dilemma: Beta-blockade renders the patient resistant to the therapeutic effects of epinephrine. The beta-2 bronchodilating and beta-1 inotropic actions of epinephrine are blunted, while unopposed alpha-adrenergic stimulation can induce severe peripheral vasoconstriction, worsening coronary ischemia and bronchoconstriction.
The Antidote: Intravenous Glucagon: Glucagon exerts positive inotropic, chronotropic, and bronchodilating effects that are completely independent of beta-adrenergic receptors . Glucagon binds to specific glucagon receptors that directly activate intracellular adenylate cyclase via Gs proteins, generating cyclic AMP (cAMP) and reversing refractory shock and bronchospasm.
Dose: 1 to 5 mg IV administered over 5 minutes, followed by a continuous infusion of 1 to 5 mg/hour titrated to hemodynamic recovery.
Renal Impairment, End-Stage Renal Disease, and Hemodialysis Protocols
Renal Excretion: Because sodium fluorescein is cleared primarily via glomerular filtration, patients with chronic kidney disease (CKD) experience prolonged clearance, with chromaturia and yellow skin discoloration persisting for several days.
Nephrotoxicity Assessment: Unlike radiopaque iodinated contrast media, sodium fluorescein is not inherently nephrotoxic at standard diagnostic doses (500 mg). It does not induce acute tubular necrosis or contrast-induced nephropathy.
Hemodialysis Patients: Sodium fluorescein is water-soluble, has low molecular weight (376 Da), and is efficiently cleared by hemodialysis . Angiography can be performed safely; scheduling the procedure on the day of or the morning immediately preceding regularly scheduled hemodialysis facilitates rapid systemic clearance.
Pregnancy and Lactation Safety Guidelines
Pregnancy (FDA Category C):
Sodium fluorescein rapidly traverses the placental barrier and enters fetal circulation, appearing in amniotic fluid.
Although animal studies have not demonstrated teratogenicity, adequate well-controlled studies in pregnant women do not exist.
Clinical Standard: Fluorescein angiography should be avoided during pregnancy , particularly during the first trimester of organogenesis, unless an acute, sight-threatening condition (e.g., suspected choroidal neovascularization, occlusive vasculitis, or ocular tumor) leaves no diagnostic alternative.
Lactation / Breastfeeding Protocol:
Sodium fluorescein is actively excreted into human breast milk for up to 48 hours post-injection.
Ingested fluorescein enters infant circulation. Because infant skin and immature retinas are thin and highly vulnerable to light-induced damage, exposure to blue daylight can trigger phototoxic reactions in infants with circulating fluorescein.
Mandatory Clinical Instruction: Nursing mothers must be instructed to express and discard (pump and dump) breast milk for 24 to 48 hours following sodium fluorescein administration before resuming direct breastfeeding.
Prophylactic Premedication Regimen for Documented Prior Reactors
If fluorescein angiography is medically essential in a patient with a documented history of a prior mild-to-moderate allergic reaction, a formal oral corticosteroid and antihistamine premedication protocol must be executed: Standard 13-Hour Prophylactic Premedication Protocol:
- 1. Prednisone 50 mg orally ──► 13 hours prior to angiography
- 2. Prednisone 50 mg orally ──► 7 hours prior to angiography
- 3. Prednisone 50 mg orally ──► 1 hour prior to angiography
- 4. Diphenhydramine 50 mg PO ──► 1 hour prior to angiography
- (Optional: Add Famotidine 20 mg orally 1 hour prior to angiography)
Clinical Caution: Premedication significantly reduces the incidence of mild and moderate cutaneous reactions (urticaria, rash), but it does not guarantee absolute protection against severe anaphylactic shock . Full emergency resuscitative readiness is mandatory for all procedures.